Laboratory Co. of America Holdings (NYSE:LH) Shares Purchased by Intrust Bank NA

Intrust Bank NA boosted its position in shares of Laboratory Co. of America Holdings (NYSE:LH) by 4.7% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 3,177 shares of the medical research company’s stock after buying an additional 144 shares during the period. Intrust Bank NA’s holdings in Laboratory Co. of America were worth $729,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Allstate Corp purchased a new stake in Laboratory Co. of America in the 4th quarter valued at $591,000. Brown Brothers Harriman & Co. boosted its stake in shares of Laboratory Co. of America by 46.4% during the fourth quarter. Brown Brothers Harriman & Co. now owns 653 shares of the medical research company’s stock worth $150,000 after buying an additional 207 shares during the period. DnB Asset Management AS boosted its stake in shares of Laboratory Co. of America by 6.1% during the fourth quarter. DnB Asset Management AS now owns 36,513 shares of the medical research company’s stock worth $8,373,000 after buying an additional 2,113 shares during the period. Pictet Asset Management Holding SA grew its holdings in shares of Laboratory Co. of America by 11.3% during the fourth quarter. Pictet Asset Management Holding SA now owns 48,942 shares of the medical research company’s stock worth $11,223,000 after buying an additional 4,988 shares during the last quarter. Finally, Nomura Asset Management Co. Ltd. raised its stake in Laboratory Co. of America by 0.4% during the 4th quarter. Nomura Asset Management Co. Ltd. now owns 39,014 shares of the medical research company’s stock valued at $8,947,000 after acquiring an additional 172 shares during the last quarter. Hedge funds and other institutional investors own 95.94% of the company’s stock.

Analyst Ratings Changes

LH has been the topic of a number of analyst reports. Bank of America lifted their price objective on shares of Laboratory Co. of America from $262.00 to $271.00 and gave the company a “buy” rating in a research report on Friday, December 13th. Morgan Stanley boosted their price target on Laboratory Co. of America from $260.00 to $270.00 and gave the stock an “overweight” rating in a research note on Tuesday, December 17th. Evercore ISI raised Laboratory Co. of America from an “in-line” rating to an “outperform” rating and lifted their price objective for the stock from $260.00 to $265.00 in a report on Tuesday, January 7th. Barclays lowered their target price on Laboratory Co. of America from $271.00 to $260.00 and set an “equal weight” rating on the stock in a report on Friday, February 7th. Finally, UBS Group decreased their price objective on shares of Laboratory Co. of America from $293.00 to $286.00 and set a “buy” rating on the stock in a research report on Tuesday, January 28th. Four investment analysts have rated the stock with a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $269.92.

Insiders Place Their Bets

In related news, Director Kerrii B. Anderson sold 500 shares of the firm’s stock in a transaction that occurred on Wednesday, March 5th. The shares were sold at an average price of $255.63, for a total value of $127,815.00. Following the transaction, the director now owns 13,166 shares in the company, valued at approximately $3,365,624.58. This trade represents a 3.66 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, EVP Der Vaart Sandra D. Van sold 1,314 shares of the business’s stock in a transaction that occurred on Tuesday, February 25th. The stock was sold at an average price of $251.30, for a total transaction of $330,208.20. Following the sale, the executive vice president now owns 2,171 shares of the company’s stock, valued at approximately $545,572.30. This represents a 37.70 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 14,500 shares of company stock valued at $3,577,572 over the last quarter. Company insiders own 0.85% of the company’s stock.

Laboratory Co. of America Stock Performance

Shares of NYSE LH opened at $229.75 on Friday. The company has a 50-day simple moving average of $244.80 and a 200-day simple moving average of $234.58. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.44 and a quick ratio of 1.30. The company has a market cap of $19.23 billion, a PE ratio of 26.05, a price-to-earnings-growth ratio of 1.71 and a beta of 1.12. Laboratory Co. of America Holdings has a 12 month low of $191.97 and a 12 month high of $258.59.

Laboratory Co. of America (NYSE:LH) last released its earnings results on Thursday, February 6th. The medical research company reported $3.45 EPS for the quarter, beating the consensus estimate of $3.40 by $0.05. Laboratory Co. of America had a return on equity of 15.29% and a net margin of 5.73%. On average, equities analysts anticipate that Laboratory Co. of America Holdings will post 16.01 earnings per share for the current year.

Laboratory Co. of America Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Wednesday, March 12th. Investors of record on Thursday, February 27th were given a dividend of $0.72 per share. This represents a $2.88 annualized dividend and a yield of 1.25%. The ex-dividend date of this dividend was Thursday, February 27th. Laboratory Co. of America’s dividend payout ratio (DPR) is 32.65%.

Laboratory Co. of America Profile

Labcorp Holdings, Inc engages in providing medical testing services. The company was founded on April 16, 2024 and is headquartered in Burlington, NC.